Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe.

Abstract

PURPOSE:

To evaluate physician use of prostaglandins (latanoprost, travoprost, and bimatoprost) in the United States (US) and Europe (EU).

METHODS:

One thousand multiple-choice surveys were distributed via e-mail in the US and EU.

RESULTS:

The authors received 71 responses (US 40 [8%] and EU 31 [6%]). Physicians preferred prostaglandin monotherapy (US 39 [98%] and EU 22 [71%], p=0.003), usually latanoprost (US 32 [80%] and EU 22 [71%], p=0.45). When more efficacy was required, US physicians would typically switch (23 [58%]) and EU physicians would add therapy (22 [71%], p=0.007). In both continents 45% of respondents stated bimatoprost was more efficacious.

CONCLUSIONS:

US and EU physicians prefer prostaglandin monotherapy, most commonly latanoprost. Bimatoprost is often perceived as more effective, but having a higher incidence of conjunctival hyperemia.

• Authors: W C Stewart, J A Stewart, L A Nelson, B Kruft
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2008 Mar-Apr Vol. 18 Issue 2 Pg. 199-204 ISSN: 1120-6721 [Print] United States
• PMID: 18320511 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amides
• Antihypertensive Agents
• Prostaglandins F, Synthetic
• Cloprostenol
• Latanoprost
• Bimatoprost
• Travoprost

Topics

• Amides (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Attitude of Health Personnel
• Bimatoprost
• Cloprostenol (analogs & derivatives, therapeutic use)
• Europe
• Glaucoma (drug therapy)
• Health Knowledge, Attitudes, Practice
• Health Services Research
• Health Surveys
• Humans
• Latanoprost
• Ophthalmology
• Practice Patterns, Physicians'
• Prostaglandins F, Synthetic (therapeutic use)
• Surveys and Questionnaires
• Travoprost
• United States